Skip to main content

Peer Review reports

From: A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Original Submission
8 Jul 2022 Submitted Original manuscript
13 Jul 2022 Reviewed Reviewer Report
21 Jul 2022 Reviewed Reviewer Report - Kirill Skorobogatykh
2 Aug 2022 Author responded Author comments - Shuu-Jiun Wang
5 Sep 2022 Reviewed Reviewer Report
12 Sep 2022 Reviewed Reviewer Report - Kirill Skorobogatykh
Resubmission - Version 2
2 Aug 2022 Submitted Manuscript version 2
Publishing
15 Sep 2022 Editorially accepted
21 Nov 2022 Article published 10.1186/s10194-022-01514-9

You can find further information about peer review here.

Back to article page